The presence and depth of urothelial cancer involvement in the prostatic urethra can significantly affect the management of a patient with non-muscle invasive bladder cancer. This article presents an overview…
High-grade T1 (HGT1) urothelial carcinoma is an invasive disease with high predisposition for recurrence and progression. The optimal treatment of HGT1 disease remains controversial. Clinical HGT1 disease represents a heterogeneous…
For treating patients with superficial bladder cancer and a moderate-to-high risk of tumor recurrence or progression, intravesical BCG has been the key development of the last generation. However, BCG has…
Bacillus Calmette-Guérin has been established as the primary treatment of high-risk non-muscle invasive bladder cancer. If patients do not respond or later recur, the most reliable treatment option is cystectomy….
Perioperative intravesical chemotherapy has a well-established role in the treatment of non-muscle invasive bladder cancer. There are multiple agents that can be used in this fashion with varying properties. Although…
This article summarizes the current literature on office-based management of low-grade, noninvasive bladder cancer. Discussion includes differences in recurrence and progression rates between neoplasm grades and stages, role of visual…
This article provides an overview of intravesical chemotherapy agents used for non–muscle invasive bladder cancer; summarizes the evidence on single-dose perioperative administration, induction therapy, and maintenance therapy; and briefly discusses…
As of 2012, bladder cancer is the fourth most common cancer afflicting men and ninth most common cancer in women. Nearly 80% of all bladder cancer diagnoses are non-muscle invasive…
Sam S. Chang, MD, FACS, Editor As the second most frequent genitourinary malignancy, non-muscle invasive bladder represents a significant, heterogeneous disease that urologists commonly diagnose, evaluate, and treat. The range…
